Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of “Hold” by Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have received a consensus recommendation of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $75.00.

Separately, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $0.53 on Thursday. The company has a market capitalization of $6.95 million, a PE ratio of -0.29 and a beta of 0.50. The company has a 50 day simple moving average of $0.51 and a two-hundred day simple moving average of $1.14. Reviva Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $17.20.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.19. Research analysts predict that Reviva Pharmaceuticals will post -2.96 EPS for the current year.

Institutional Trading of Reviva Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of Reviva Pharmaceuticals in the 2nd quarter worth about $31,000. Lido Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the 3rd quarter valued at about $37,000. NewEdge Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the 1st quarter valued at about $58,000. State Street Corp grew its stake in Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after purchasing an additional 256,500 shares during the period. Finally, Geode Capital Management LLC grew its stake in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the period. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.